Molecular markers in head and neck squamous cell carcinoma: Their biological function and prognostic significance

Annals of Otology, Rhinology and Laryngology

Volumn 110, Issue 3, 2001, Pages 221-228

  Smith, B D ^a   Haffty, B G ^a   Sasaki, C T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Head and neck cancer; Molecular markers; Prognostic factors

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; VASCULOTROPIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; DISEASE COURSE; HEAD AND NECK CANCER; HIGH RISK POPULATION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

EID: 0035104374     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940111000304     Document Type: Article

References (89)

1. Estimates of the worldwide frequency of sixteen major cancers in 1980
2. Cancers of the oral cavity and pharynx in the United States: An epidemiologic overview
3. Concurrent chemoradiation in the treatment of head and neck cancer
4. Hyperfractionated irradiation with or without concurrent chemotherapy of locally advanced head and neck cancer
5. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors
6. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials
7. Oxygen delivery: Implications for the biology and therapy of solid tumors
8. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial
9. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer
10. Combined effects of angiostatin and ionizing radiation in antitumour therapy
11. Chemotherapy for squamous cell carcinoma of the head and neck: The future is now
12. Hypoxia-specific cytotoxins in cancer therapy
13. Single-agent paclitaxel plus ifosfamide in the treatment of head and neck cancer
14. Ploidy in head and neck cancer: A review and meta-analysis
15. p53, guardian of the genome
16. The regulation of p53 function: Steiner Award lecture
17. Braking the cycle
18. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
19. Thymocyte apoptosis induced by p53-dependent and independent pathways
20. p53 is required for radiation-induced apoptosis in mouse thymocytes
21. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
22. The molecular regulation of apoptosis and implications for radiation oncology
23. Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy
24. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy
25. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
26. The cellular oncogene p53 can be activated by mutagenesis
27. Increased expression of mutant forms of p53 oncogene in primary lung cancer
28. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma
29. p53 expression: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma
30. Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications
31. Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study
32. p53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer
33. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck
34. Prognostic indicators for squamous cell carcinoma of the oral cavity: A clinicopathologic correlation
35. Biological indicators of survival in patients treated by surgery for squamous cell carcinoma of the oral cavity and oropharynx
36. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy
37. Tumor angiogenesis: Therapeutic implications
38. Tumor angiogenesis
39. Regulators of angiogenesis
40. VEGF/VPF: The angiogenesis factor found?
41. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
42. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
43. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
44. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression
45. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells
46. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
47. Tumor angiogenesis as a prognostic factor in oral cavity tumors
48. Cell proliferation and tumor angiogenesis in oral squamous cell carcinoma
49. Tumor angiogenesis as a prognostic factor in early oral tongue cancer
50. Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma
51. Angiogenesis as a prognostic marker in early head and neck cancer
52. Vascular endothelial growth factor in squamous cell head and neck carcinoma: Expression and prognostic significance
53. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia
54. Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: Its association with tumour progression and p53 gene status
55. Vascular endothelial growth factor expression in head and neck squamous cell carcinoma
56. A novel cyclin encoded by a bc 11-linked candidate oncogene
57. D-type cyclins
58. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit
59. Clinical application of fluorescence in situ hybridization for chromosome 11q13 analysis in head and neck cancer
60. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma
61. Chromosome 11q13 amplification in head and neck squamous cell carcinoma, association with poor prognosis
62. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: Prognostic significance and clinical implications
63. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression
64. Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma
65. Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer
66. Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: Correlation with clinical outcome
67. Chromosome 11q13 gene amplifications in oral and oropharyngeal carcinomas: No correlation with subclinical lymph node invasion and disease recurrence
68. Prognostic significance of cyclin D1 protein levels in early stage larynx cancer treated with primary radiation
69. Alternate splicing produces a novel cyclin D1 transcript
70. Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck
71. Elevated levels of transforming growth factor-alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer
72. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
73. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways
74. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells
75. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells
76. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
77. Enhancement of sensitivity of human squamous carcinoma cells to radiation by epidermal growth factor
78. Differences in EGF related radiosensitization of human squamous carcinoma cells with high and low numbers of EGF receptors
79. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities
80. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer
81. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
82. Epidermal growth factor receptor expression in primary laryngeal cancer: An independent prognostic factor of neck node relapse
83. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
84. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy
85. Molecular staging of head and neck squamous carcinoma
86. Gene therapy for head and neck cancer: Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21)
87. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer
88. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
89. Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer